Awstralja - Ingliż - APVMA (Australian Pesticides and Veterinary Medicines Authority)

axichem pty ltd - methomyl; methanol - liquid concentrate - methomyl carbamate-methylcarbamate active 225.0 g/l; methanol solvent other 593.0 g/l - insecticide

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

stryker australia pty ltd - 34170 - prosthesis, internal, spine, vertebral body - when used as a thoracolumbar vertebral body replacement device, the system is intended for use in the thoracolumbar spine to replace collapsed, damaged, or unstable vertebral bodies due to tumour or trauma. it is designed to provide anterior spinal column support even in the absence of fusion for a prolonged period. when used as a cervical vertebral body replacement device, the system is intended for use in the cervical spine in skeletally mature patients to replace diseased or damaged vertebral bodies due to tumour, trauma, osteomyelitis, or for reconstruction following corpectomy. the implants are intended to be used with supplemental internal fixation appropriate for the implanted level and may be used with allograft or autograft.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - emtricitabine, quantity: 200 mg; tenofovir alafenamide fumarate, quantity: 28.04 mg; rilpivirine hydrochloride, quantity: 27.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; povidone; croscarmellose sodium; polysorbate 20; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; ferrosoferric oxide - odefsey is indicated as a complete regimen for the treatment of hiv-1 infection in adults and adolescents (12 years and older with body weight at least 35 kg) with plasma hiv-1 rna <= 100,000 copies/ml at the start of therapy. the patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of odefsey.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eliglustat tartrate, quantity: 100 mg (equivalent: eliglustat, qty 84.4 mg) - capsule, hard - excipient ingredients: lactose monohydrate; hypromellose; microcrystalline cellulose; glycerol dibehenate; iron oxide yellow; gelatin; indigo carmine aluminium lake; titanium dioxide; mica; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - cerdelga is indicated for the long-term treatment of adult patients with gaucher disease type 1 (gd1).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

emergo asia pacific pty ltd t/a emergo australia - 34170 - prosthesis, internal, spine, vertebral body - the vertebral body replacement implant is intended for use for stabilization and reconstruction in complete or incomplete corpectomy due to destructive damage of the vertebral body, such as can be caused for instance by tumors, fractures or inflammations in defined regions of the spine.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

guerbet australia pty ltd - gadoteric acid, quantity: 279.32 mg/ml - injection, solution - excipient ingredients: meglumine; water for injections - dotarem is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see clinical studies).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

guerbet australia pty ltd - gadoteric acid, quantity: 279.32 mg/ml - injection, solution - excipient ingredients: meglumine; water for injections - dotarem is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see clinical studies).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

guerbet australia pty ltd - gadoteric acid, quantity: 279.32 mg/ml - injection, solution - excipient ingredients: meglumine; water for injections - dotarem is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see clinical studies).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - miglustat, quantity: 100 mg - capsule, hard - excipient ingredients: magnesium stearate; povidone; sodium starch glycollate; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid; potassium hydroxide; industrial methylated spirit; ammonia; sorbitan monolaurate; gelatin; sodium lauryl sulfate - zavesca is indicated for the oral treatment of patients with mild to moderate type 1 gaucher disease, for whom enzyme replacement therapy is not a therapeutic option. zavesca is indicated for the treatment of the progressive neurological manifestations in adult and paediatric patients with niemann-pick type c disease.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - omeprazole, quantity: 20 mg - capsule - excipient ingredients: titanium dioxide; dibasic sodium phosphate; purified talc; mannitol; hypromellose; quinoline yellow; maize starch; sodium lauryl sulfate; sucrose; gelatin; polysorbate 80; macrogol 6000; purified water; methacrylic acid copolymer - the relief of heartburn and other symptoms associated with gastro-oesophageal reflux disease (gord). treatment and prevention of relapse in erosive oesophagitis. treatment of duodenal and gastric ulcer. combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection. treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs (nsaids). prevention of gastric and duodenal ulcers and erosions associated with nsaids in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. long-term prevention of relapse in gastric and duodenal ulceration in patients proven to be h.pylori negative or in whom eradication is inappropriate (eg. the elderly) or ineffective. treatment of zollinger-ellison syndrome.